Vera Therapeutics (NASDAQ:VERA) Releases Earnings Results, Misses Estimates By $0.05 EPS

Vera Therapeutics (NASDAQ:VERA) released its earnings results on Wednesday. The company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.34) by ($0.05), Zacks reports. During the same quarter in the prior year, the company earned ($0.72) earnings per share.

Vera Therapeutics Stock Up 1.6%

VERA stock opened at $42.35 on Friday. The stock has a 50-day simple moving average of $46.53 and a two-hundred day simple moving average of $35.35. Vera Therapeutics has a twelve month low of $18.53 and a twelve month high of $56.05. The firm has a market capitalization of $2.97 billion, a PE ratio of -10.61 and a beta of 1.16. The company has a quick ratio of 12.21, a current ratio of 12.21 and a debt-to-equity ratio of 0.19.

Wall Street Analyst Weigh In

VERA has been the subject of a number of recent analyst reports. TD Cowen restated a “buy” rating on shares of Vera Therapeutics in a research note on Friday, December 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Vera Therapeutics in a research report on Wednesday, January 21st. HC Wainwright restated a “buy” rating and set a $90.00 price objective on shares of Vera Therapeutics in a report on Friday, November 28th. The Goldman Sachs Group boosted their target price on shares of Vera Therapeutics from $55.00 to $95.00 and gave the company a “buy” rating in a research note on Friday, December 19th. Finally, Pivotal Research set a $73.00 target price on shares of Vera Therapeutics in a research report on Friday, December 5th. Nine research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $78.80.

Insider Buying and Selling

In other news, Director Patrick G. Enright bought 5,882 shares of the stock in a transaction on Thursday, December 11th. The shares were acquired at an average cost of $42.50 per share, for a total transaction of $249,985.00. Following the purchase, the director directly owned 5,882 shares of the company’s stock, valued at $249,985. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Sean Grant sold 4,949 shares of the business’s stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $41.98, for a total transaction of $207,759.02. Following the transaction, the chief financial officer owned 114,181 shares of the company’s stock, valued at $4,793,318.38. This trade represents a 4.15% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 33,490 shares of company stock valued at $1,405,910 in the last three months. Insiders own 16.30% of the company’s stock.

Institutional Investors Weigh In On Vera Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Los Angeles Capital Management LLC bought a new position in Vera Therapeutics in the 4th quarter worth about $46,000. Aster Capital Management DIFC Ltd purchased a new position in shares of Vera Therapeutics during the fourth quarter worth about $71,000. Quantbot Technologies LP bought a new position in shares of Vera Therapeutics in the second quarter worth approximately $51,000. Sandia Investment Management LP purchased a new stake in Vera Therapeutics in the fourth quarter valued at approximately $127,000. Finally, FORA Capital LLC bought a new stake in Vera Therapeutics during the fourth quarter valued at approximately $206,000. Institutional investors own 99.21% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.